Study on the binding capacity of IgA1 from patients with IgA nephropathy to human mesangial cells

AIM: To examine and compare the ability of serum IgA 1, from both the patients with IgA nephropathy(IgAN) and the healthy control, to bind to human mesangial cells(HMC). METHODS: Serum IgA was isolated with jacalin column, heated to aggregated form(IgA₁) and labeled with ¹²⁵I]. Binding capacity of IgA₁ to primary HMC was evaluated by radioligant binding assay, specificity of binding was determined by competitive inhibition, and relative affinities was compared by cross competitive inhibition. RESULTS: Both IgA₁ from normal control and patients with IgAN bound to MC in a dose-dependent, saturatable manner, but the binding of IgA₁ from patients was saturated at approximately 200 pmol while that from healthy was at 400 pmol. The Scatchard analysis revealed a Kd of(8.9±2.1)×10^-8 mol/L for patient' s IgA₁ versus(4.3±1.2)×10^-7mol/L for normal IgA₁(P<0.05). Competition inhibition showed that both serum albumin and IgG could not block the binding of IgA₁ to HMC while mIgA 1 could partially block that. Cross competition inhibition demonstrated that patient' s IgA₁ blocked normal IgA₁ binding significantly(P<0.01), however, normal IgA₁ was unable to inhibit the binding of patient' s IgA₁. CONCLUSIONS: ①There are IgA binding proteins or receptors on mesangial cells. ②IgA₁ from patients with IgAN has a higher binding capacity than that from healthy.